News >

Pyrotinib Shows Early Promise in HER2+ Breast Cancer

Jason Harris
Published: Tuesday, May 23, 2017

breast cancer
In phase I results from China published in the Journal of Clinical Oncology, oral pyrotinib (HTI-1001) was well-tolerated and showed antitumor activity in women with HER2-positive breast cancer.

“We need additional studies to evaluate this new compound and questions need to be answered on what chemotherapy regimen it will be combined with and whether it is less toxic or more efficacious than our current anti-HER2 medications.”
Ma F, Li Q, Chen S, et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-erbb receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer [published online May 12, 2017]. J Clin Oncol. doi: 10.1200/JCO.2016.69.6179.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication